This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
IL6 is targeted as part of treatment in adoptive cell therapy (ACT) because of its protumor effects and its role in the cytokine release syndrome. However, another major role of IL6 is to polarize naïve CD4+ T cells from Tregs to Th17 cells. While Th17 T cells are associated with autoimmunity, they are present around many different solid tumor cancers and their role in tumor microenvironments is unclear. In this issue of Cancer Research, Knochelmann and colleagues show that Th17 cells with less in vitro expansion in IL6-driven Th17 ACT provide greater solid tumor control and robust immune memory, highlighting advancement in the field of ACT application to solid tumor immunotherapy.
See related article by Knochelmann et al., p. 3920
Footnotes
Cancer Res 2020;80:3795–6
- Received July 22, 2020.
- Accepted July 22, 2020.
- Published first September 15, 2020.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
Volume 80, Issue 18
